Table 2.
Menopausal status and reported treatments for HMB among all responders, and by original ECLIPSE trial allocations over 10-year follow-up period
| All responders, n (%) (n = 206) | Allocated to LNG-IUS, n (%) (n = 110) | Allocated to usual medical treatment, n (%) (n = 96) | |
|---|---|---|---|
| Menopausal status | |||
| Premenopausal | 32 (15.5) | 16 (15.5) | 16 (16.6) |
| Postmenopausal | 106 (51.5) | 54 (49.1) | 52 (54.1) |
| Undergone hysterectomy | 34 (16.5) | 18 (16.4) | 16 (16.6) |
| Perimenopausal or uncertain | 32 (15.5) | 21 (19.1) | 11 (11.4) |
| Missing | 2 (0.9) | 1 (0.9) | 1 (1.0) |
| Using menopausal hormone therapy | 28 (13.6) | 16 (14.5) | 12 (12.5) |
| Still experiencing heavy menstrual bleeding | 12 (5.8) | 6 (5.5) | 6 (6.3) |
| Using LNG-IUS at response to 10-year follow-up | 56 (27.2) | 38 (34.5) | 18 (18.8) |
|
| |||
| Classes of treatments used between 5 and 10 years | |||
| LNG-IUS | 67 (32.5) | 47 (42.7) | 20 (20.8) |
| Usual medical treatment | 29 (14.1) | 10 (9.1) | 19 (19.8) |
| LNG-IUS and usual medical treatment | 21 (10.2) | 11 (10.0) | 10 (10.4) |
| None | 89 (43.2) | 42 (38.2) | 47 (48.9) |
|
| |||
| Standard medical treatments used between 5 and 10 years | |||
| Tranexamic acid | 24 (11.6) | 7 (6.4) | 17 (17.7) |
| Mefenamic acid | 6 (2.9) | 3 (2.7) | 3 (3.1) |
| Norethisterone | 13 (6.3) | 4 (3.6) | 9 (9.3) |
| Desogestrel | 3 (1.4) | 0 | 3 (3.1) |
| Oral contraceptives | 8 (3.9) | 3 (2.7) | 5 (5.2) |
| Medroxyprogesterone acetate injection | 1 (<1) | 1 (<1) | 0 |
| Naproxen | 1 (<1) | 0 | 1 (<1) |
|
| |||
| Surgical intervention for HMB | |||
| Hysterectomy | 34 (16.5) | 18 (16.4) | 16 (16.6) |
| Endometrial ablation | 26 (12.6) | 10 (9.1) | 16 (16.6) |
HMB = heavy menstrual bleeding. LNG-IUS = levonorgestrel-releasing intrauterine system.